Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/30/14  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. David Buswell

Wrong David Buswell?

Chief Operating Officer and Chief...

Local Address: Atlantic City, New Jersey, United States
Immune Response BioPharma Inc
2711 Centerville Road Suite 400
Wilmington , Delaware 19808
United States

Company Description: Immune Response BioPharma, Inc. TM is a Delaware corporation and is a leading vaccine development company that has its own proprietary drug pipeline under...   more
Background

Employment History

Education

  • Master’s degree MA , Management & Leadership
    Liberty University
  • Bachelor’s degree , Business & Commerce
    University of Mary Washington
  • Masters Degree
  • Master’s Degree , Management & Leadership
    Liberty University
13 Total References
Web References
Executive Team
www.immuneresponsebiopharma.com, 30 Aug 2014 [cached]
Chief Operating Officer & Chief Financial Officer & CEO: Mr. David Buswell
Mr. David Buswell is founder of Immune Response BioPharma, and is Chief Operating Officer, CFO, President & acting CEO and is Chairman of the Board of Directors. Mr. Buswell holds a Bachelor’s degree in Business & Commerce from the University of Mary Washington, and a Master’s degree MA in Management & Leadership from Liberty University.
March 23rd 2011 Immune Response BioPharma ...
immuneresponsebiopharma.com [cached]
March 23rd 2011 Immune Response BioPharma Chief Mr. Buswell to be Awarded Masters Degree
...
The low cost of maintenance and ownership of our domain hosted on the Microsoft platform gives us a strong platform to showcase our company, clinical pipeline and  future company developments†Mr. Buswell COO IRBP.
...
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va and holds a Master’s Degree in Management & Leadership from Liberty University.
...
I am pleased with the progress we are making and look forward to banner years in the future†Mr. Buswell COO IRBP.
...
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va and holds a Master’s Degree in Management & Leadership from Liberty University.
...
I would expect one of the larger players to develop NeuroVax, as this is an $18 billion dollar market and a safe effective drug like this would cost big pharma a fortune to develop this type of technology on their own†Mr. Buswell COO IRBP.
...
REMUNE is a monster drug that data proves used as a standalone treatment without HAART has proven to be extremely effective†Mr. Buswell COO IRBP.
“Immune Response BioPharma is a sepsis drug company and will partner NeuroVax and REMUNE to pave the way for our new sepsis drug Sepsicillin a first in class BPI formulation antibiotic. I have dedicated my life to fighting sepsis after my father passed away from sepsis shock, this is a deep personal issue for me. We have a great pipeline and I am just getting warmed up building this company we will get the financing resolved†Mr. Buswell COO IRBP.
...
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va and holds a Master’s Degree in Management & Leadership from Liberty University.
...
“NeuroVax is a novel treatment option that has the opportunity to become the gold standard of care for patients suffering with MS. Our friends at Oregon Health & Science University Dr. Vandenbark and Dr. Bourdette are experts in this field and have developed a world class treatment for MS. It is a shame funding has held this important drug off of the market†COO Mr. Buswell of IRBP.
...
We will hold a joint conference call in the coming future with our friends at OHSU and invite biotech investors and investment bankers to join our call to discuss NeuroVax and the opportunity along with plans for a phase 2 dose ranging trial, the date and time will be announced in the future†Mr. Buswell COO IRBP.
...
I have asked many of the old IRC employees to help me with this effort and I welcome those with expertise in this area to assist as well†COO Mr. Buswell.
“Manufacturing will be the biggest hurdle for REMUNE at this point it has been tested safely in over 25 clinical trials and the data is a mixed bag on efficacy there is no perfect solution. REMUNE does many things well and the benefits appear to outweigh the limited risks at this point. It has a low toxicity profile compared to the HAART drugs, it is extremely safe, shows significant CD+8 T Cell counts, and reduces the peak viral load†COO Mr. Buswell.
...
I pray that God takes action against these evil people†COO Mr. Buswell.
...
I am not afraid of cowards†COO Mr. Buswell
...
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va and holds a Master’s Degree in Management & Leadership from Liberty University.
...
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va and holds a Master’s Degree in Management & Leadership from Liberty University.
...
My message to the HIV/AIDS patients is  I am not going to let you die, DEMAND your REMUNE, hang in there until I can get you the vaccine†COO Mr. Buswell
...
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va and holds a Master’s Degree in Management & Leadership from Liberty University.
...
We believe REMUNE holds the safest and most effective treatment option for HIV/AIDS patients, the HAART drugs are just plain toxic and poisonous, I am committed to saving lives and getting patients the vaccine†Mr. Buswell COO .
“REMUNE is a winner hands down and see the vaccine as the gold standard of treatment, eventually 90% market share , as soon as we have clarity on CGMP’s manufacturing we will press forward on an NDA for REMUNE. I believe we are close to receiving funding and support from a prominent businessman and we will move forward building a dynamic pharmaceutical company to save lives. Those who wait to partner with IRBP and wait to collaborate including big pharma will lose out†Mr. Buswell COO.
...
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va and holds a Master’s Degree in Management & Leadership from Liberty University.
...
COO Mr. David Buswell of IRBP will be providing a company overview and presentation on our exciting plans for the future. This is a chance to meet COO Mr. Buswell and will provide potential investors an opportunity to discover why IRBP is a dynamic BioPharmaceutical with a solid pipeline of treatments for AIDS, MS and Sepsis Shock.
...
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va and holds a Master’s Degree in Management & Leadership from Liberty University.
...
I would say to the FDA and governments around the globe give the millions the vaccine immediately and help save lives, As far as partnering goes I am open to equity swaps and a mid 20’s royalty percentage and cash upfront for licensing Remune and RemuneX we have a billion dollar opportunity to save lives, those who wait to partner will likely lose out†Mr. Buswell COO IRBP.
...
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va and holds a Master’s Degree in Management & Leadership from Liberty University.
...
Partial immunity is better than no immunity, saving lives is paramount to our mission†IRBP COO Mr. Buswell.
...
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va and holds a Master’s Degree in Management & Leadership from Liberty University.
...
NeuroVax and Remune are great treatments for MS and HIV/AIDS to leave those vaccines half way completed would be tragic when the therapies can help so many people across the globe†Mr. Buswell COO.
“While it has been a slow process of building the new company in the past few months, as I was completing my master’s degree with Liberty University and in the process moving the last month, I look forward to building IRBP in the coming months and years ahead with a blend of new drug discovery in the infectious disease area with the sepsis drug and driving ahead to bring NeuroVax and Remune to commercialization. I am also pleased to announce Mr. Eric Swanson an accredited investor and a media & public relations expert joins IRBP to handle our media and Investor Relations duties as President of Media and IR, I thank Mr. Swanson for his support†Mr. Buswell COO.
...
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va and holds a Master’s Degree in Management & Leadership from Liberty University.
...
Restarting the Remune program and the company is the right thing to do, it is paramount that action be taken to halt a pandemic of epic proportions†Mr. Buswell COO IRBP.
“Those who have criticized Remune in the past are out of touch with reality there is no perfect solution to this
Chief Operating Officer & Chief Financial ...
immuneresponsebiopharma.com, 25 Nov 2011 [cached]
Chief Operating Officer & Chief Financial Officer Mr. David Buswell
Mr. David Buswell is founder of Immune Response BioPharma, and is Chief Operating Officer, CFO and is on the Board of Directors. Mr. Buswell holds a Bachelor’s degree in Business & Commerce from the University of Mary Washington, and a Master’s degree MA in Leadership & Management from Liberty University.
"This recent issuance of U.S. 8,053,197 ...
www.healthcareprnews.com, 19 May 2012 [cached]
"This recent issuance of U.S. 8,053,197 is a key patent in that it extends key IP coverage including FOXP3+ Expression Technology related to the delivery and composition of NeuroVax with TCR peptide vaccines including the addition of estrogen to boost the vaccine potential in women suffering from MS." said Mr. David Buswell, IRBP Chief Executive Officer.
...
David Buswell Immune Response BioPharma, Inc. CEO 244 5th avenue suite 1727
Funding for the trials should not ...
www.biospace.com, 14 Jan 2011 [cached]
Funding for the trials should not be an issue as this is an important drug/vaccine that perhaps is the best treatment option for MS and it may become treatment of choice for MS. I believe the Funding will come and the company will select the right partners to make this treatment a reality for those suffering from MS, as well the manufacturing process and partners look promising†Chief Operating Officer, Mr. Buswell.
...
Mr. David Buswell Chief of Immune Response BioPharma @ (540)-760-0535
Mr. Buswell is a University of Mary Washington Business & Commerce Graduate in Fredericksburg, Va
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.